Investigation of the Potential Effect of Complement 5 on Transplantation Outcome by Bioinformatics Tools
DOI:
https://doi.org/10.5254/s1q4yy85Keywords:
Complement 5, Bioinformatic, TransplantationAbstract
Introduction. Activation of the complement system following transplantation may result in allograft rejection. Our study aimed to evaluate the potential relationship between factors affecting kidney transplant success and complement 5 (C5) using bioinformatic tools. Methods. GenCards and Genemania were used to provide the genetic functional information belonging to the C5 gene, and genomic browsers of STRING, UCSC, KEGG were used to reveal interactions with other genes and various pathways. MiRDB was used to specify the miRNAs that were associated with the C5 gene. The UniProt database was used to determine the tissues that expressed the C5 gene using protein-protein interactions. Results. In the bioinformatic analyses performed, high levels of C5 gene expression were found in the naiive kidney. Twenty-five genes were found to be strongly associated with C5. Fifty-four miRNAs targeting the C5 gene were specified. The C5 gene was found to be involved in biologic processes such as complement activation (FDR = 6.46e-22), complement binding (FDR = 2.20e-06), cytolysis (FDR = 4.82e-14), regulation of complement activation (FDR = 4.08e-24), positive regulation of vascular endothelial growth factor production (FDR = 0.0430), regulation of macrophage chemotaxis (FDR = 0.0447), activation of the immune response (FDR = 1.26e-13), leukocyte-mediated immunity (FDR = 1.41e-09), innate immune response (FDR = 3.05e-09), allograft rejection (FDR = 2.40e-12), oxidative injury response (FDR = 0.00016), and trigerring of the beginning of the complement cascade (FDR = 0.0244). Conclusions. The data obtained in this study will be used to guide future experimental investigations in the field of transplantation, and these data will give physicians with insight into allograft status following transplantation.
Downloads
References
1. Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp).2012;2:103-11.
2. Barnum SR. Complement: A primer for the coming therapeutic revolution. Pharmacol. Ther. 2017;172:63-72.
3. Tichaczek-Goska D. Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv Clin Exp Med. 2012;21:105-14.
4. Abbas A, Lichtman A, Pillai S. Effector Mechanisms of Humoral Immunity, Cellular and Molecular Immunology. 7th ed. Philadelphia: El-sevier; 2011:269-92.
5. Garred, P. et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol. Rev. 2016:74–97.
6. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part ý molecular mechanisms of activation and regulation. Front Immunol. 2015;2:262.
7. Beltrame MH, Catarino SJ, Goeldner I, Boldt ABW, José de Messias-Reason I. The lectin pathway of complement and rheumatic heart disease. Front Pediatr. 2015;21:148.
8. Poppelaars F, Faria B, Gaya da Costa M, et al. The complement system in dialysis: a forgotten story? Front Immunol. 2018;25:71.
9. Stites, E., Le Quintrec, M. & Thurman, J. M. The complement system and antibody-mediated transplant rejection. J. Immunol. 2015:5525–31.
10. Damman J, Seelen MA, Moers C, et al. Systemic complement activation in deceased donors, associated with acute rejection after renal transplantation in the recipient. Transplantation. 2011;92:163–169.
11. van Werkhoven MB, Damman J, van Dijk MCRF, et al. Complement-mediated renal inflammation induced by donor brain death: Role of renal C5a-C5aR interaction. Am. J. Transplant. 2013;13:875–882.
12. Nishi S, Imai N, Ito Y, et al. Pathological study on the relationship between C4d, CD59 and C5b-9 in acute renal allograft rejection. Clin Transplant. 2004;18:18-23.
13. van Werkhoven MB, Damman J, Daha MR, et al. Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney. Mol. Immunol. 2012;53:237–245.
14. De Vries DK, Van Der Pol P, Van Anken GE, et al. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013;95:816–820.
15. Błogowski W, Dołęgowska B, Sałata D, Budkowska M, Domański L, Starzyńska T. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation. Clin J Am Soc Nephrol. 2012;7:1843-1851.
16. https://www.genecards.org/cgi-bin/carddisp.pl?gene=C5
17. https://genemania.org/search/homo-sapiens/C5/
18. https://mirdb.org/cgi-bin/search.cgi.
20. https://www.genome.jp/kegg/pathway.html.
23. Tak W. Mak, Mary E. Saunders, Complement Editor(s): Tak W. Mak, Mary E. Saunders, The Immune Response, Academic Press, 2006, Pages 553-581, ISBN 9780120884513, https://doi.org/10.1016/B978-012088451-3.50021-1.
24. Mizuno M, Blanchin S, Gasque P, Nishikawa K, Matsuo S. High levels of complement C3a receptor in the glomeruli in lupus nephritis. Am J Kidney Dis. 2007;49:598–606.
25. Bao L, Osawe I, Haas M, Quigg RJ. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol. 2005;175:1947–1955
26. Gueler F, Rong S, Gwinner W, et al. Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol. 2008;19:2302–2312.
27. Li Q, Peng Q, Xing G, et al. Deficiency of C5aR prolongs renal allograft survival. J Am Soc Nephrol. 2010;21:1344–1353.
28. Thurman JM, Lenderink AM, Royer PA, et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol. 2007;178:1819–1828.
29. Peng Q, Li K, Smyth LA, et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23:1474–1485.
30. Liu L, Zhang Y, Duan X, et al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy. J Clin Immunol. 2014;34:224-232.
31. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am. J. Transplant. 2008;8:2684–2694.
32. Stegall MD, Diwan T, Raghavaiah S. Terminal complement decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 2011; 11:2405–2413.
33. Farrar CA, Zhou W & Sacks SH. Role of the lectin complement pathway in kidney transplantation. Immunobiology. 2016; 221:1068–1072.
34. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007; 25:1256–1264.
35. Cernoch M, Hruba P, Kollar M, et al. Intrarenal complement system transcripts in chronic antibody-mediated rejection and recurrent IgA nephropathy in kidney transplantation. Front Immunol. 2018;9:2310.
36. Ramanathan K, Padmanabhan G. MiRNAs as potential biomarker of kidney diseases: A review. Cell Biochem. Funct. 2020;38:990–1005.
37. Danger R, Paul C, Giral M, et al. Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection. PLoS ONE. 2013;8:e60702.
38. Anglicheau D, Sharma VK, Ding R, et al. MicroRNA expression profiles predictive of human renal allograft status. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:5330–5335.
39. Xu Z, Nayak D, Yang W, et al. Dysregulated MicroRNA expression and chronic lung allograft rejection in recipients with antibodies to donor HLA. American Journal of Transplantation. 2015;15:1933–1947.
40. Joshi D, Salehi S, Brereton H, et al. Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation. Liver Transplantation. 2013;19:383–394.
41. De Luca L, Trino S, Laurenzana I, et al. MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. Oncotarget. 2015;7:6676–6692.
